Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)

Robert Klamroth,1 Kingsley Hampton,2 Sonata Saulyte Trakymienė,3 Lars Korsholm,4 Manuel Carcao5 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; 3Clinic...

Full description

Bibliographic Details
Main Authors: Klamroth R, Hampton K, Saulyte Trakymienė S, Korsholm L, Carcao M
Format: Article
Language:English
Published: Dove Medical Press 2021-11-01
Series:Patient Preference and Adherence
Subjects:
Online Access:https://www.dovepress.com/illustrative-cases-from-the-pathfinder-clinical-trials-of-patients-wit-peer-reviewed-fulltext-article-PPA
_version_ 1818999817315024896
author Klamroth R
Hampton K
Saulyte Trakymienė S
Korsholm L
Carcao M
author_facet Klamroth R
Hampton K
Saulyte Trakymienė S
Korsholm L
Carcao M
author_sort Klamroth R
collection DOAJ
description Robert Klamroth,1 Kingsley Hampton,2 Sonata Saulyte Trakymienė,3 Lars Korsholm,4 Manuel Carcao5 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; 3Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; 4Biostatistics, Novo Nordisk A/S, Bagsværd, Denmark; 5Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, CanadaCorrespondence: Robert KlamrothDepartment of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, GermanyTel +49 30 130 231575Fax +49 30 130 232130Email robert.klamroth@vivantes.dePurpose: To illustrate the benefits of the extended half-life (EHL) recombinant factor VIII product N8-GP (Esperoct®, turoctocog alfa pegol) by describing individual cases of patients with severe hemophilia A treated with N8-GP in the pathfinder clinical trial program.Patients and Methods: This manuscript presents selected patient cases from the pivotal pathfinder clinical trial program, which included a number of clinical studies in adults (pathfinder 2 and 3) and children (pathfinder 5); overall results published previously. Clinical data and outcomes described in this manuscript are more detailed and derived from several interesting patient cases (five adults from pathfinder 2 and two children from pathfinder 5), who received N8-GP as prophylaxis (PPX) for their severe hemophilia A. Three of the five adults described here also underwent multiple major surgeries (for which they moved from pathfinder 2 into pathfinder 3 and later returned to pathfinder 2). New analyses on pediatric joint health from pathfinder 5 are also summarized here. Outcomes assessed included bleeding complications, improvements in quality of life, intraoperative hemostatic response, blood loss during surgery, number of blood transfusions, and annualized bleeding rates. For the pediatric patients, target joint resolution, adverse events, and annualized joint bleeding rate were also assessed, all by the treating physician.Results: Considerable improvements in treatment adherence, bleeding rates, and overall physical activity levels were demonstrated in two adult cases from the pathfinder 2 trial. N8-GP demonstrated good or excellent hemostatic coverage in three adult patients undergoing multiple major surgeries. The benefits of N8-GP for joint health and in support of children and adolescents with evolving active lifestyles were reported for several pediatric cases.Conclusion: These patient cases highlight the benefits of EHL products, such as N8-GP, for patients with severe hemophilia A. They include more challenging scenarios relating to improvements in previously poor adherence to PPX, children with active sporting lifestyles, and patients requiring multiple major surgeries.Keywords: extended half-life, factor VIII, prophylaxis, surgery, joint health
first_indexed 2024-12-20T22:23:27Z
format Article
id doaj.art-2c960f49b0f844b0a10151a59a239b6a
institution Directory Open Access Journal
issn 1177-889X
language English
last_indexed 2024-12-20T22:23:27Z
publishDate 2021-11-01
publisher Dove Medical Press
record_format Article
series Patient Preference and Adherence
spelling doaj.art-2c960f49b0f844b0a10151a59a239b6a2022-12-21T19:24:53ZengDove Medical PressPatient Preference and Adherence1177-889X2021-11-01Volume 152443245470331Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)Klamroth RHampton KSaulyte Trakymienė SKorsholm LCarcao MRobert Klamroth,1 Kingsley Hampton,2 Sonata Saulyte Trakymienė,3 Lars Korsholm,4 Manuel Carcao5 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; 3Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; 4Biostatistics, Novo Nordisk A/S, Bagsværd, Denmark; 5Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, CanadaCorrespondence: Robert KlamrothDepartment of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, GermanyTel +49 30 130 231575Fax +49 30 130 232130Email robert.klamroth@vivantes.dePurpose: To illustrate the benefits of the extended half-life (EHL) recombinant factor VIII product N8-GP (Esperoct®, turoctocog alfa pegol) by describing individual cases of patients with severe hemophilia A treated with N8-GP in the pathfinder clinical trial program.Patients and Methods: This manuscript presents selected patient cases from the pivotal pathfinder clinical trial program, which included a number of clinical studies in adults (pathfinder 2 and 3) and children (pathfinder 5); overall results published previously. Clinical data and outcomes described in this manuscript are more detailed and derived from several interesting patient cases (five adults from pathfinder 2 and two children from pathfinder 5), who received N8-GP as prophylaxis (PPX) for their severe hemophilia A. Three of the five adults described here also underwent multiple major surgeries (for which they moved from pathfinder 2 into pathfinder 3 and later returned to pathfinder 2). New analyses on pediatric joint health from pathfinder 5 are also summarized here. Outcomes assessed included bleeding complications, improvements in quality of life, intraoperative hemostatic response, blood loss during surgery, number of blood transfusions, and annualized bleeding rates. For the pediatric patients, target joint resolution, adverse events, and annualized joint bleeding rate were also assessed, all by the treating physician.Results: Considerable improvements in treatment adherence, bleeding rates, and overall physical activity levels were demonstrated in two adult cases from the pathfinder 2 trial. N8-GP demonstrated good or excellent hemostatic coverage in three adult patients undergoing multiple major surgeries. The benefits of N8-GP for joint health and in support of children and adolescents with evolving active lifestyles were reported for several pediatric cases.Conclusion: These patient cases highlight the benefits of EHL products, such as N8-GP, for patients with severe hemophilia A. They include more challenging scenarios relating to improvements in previously poor adherence to PPX, children with active sporting lifestyles, and patients requiring multiple major surgeries.Keywords: extended half-life, factor VIII, prophylaxis, surgery, joint healthhttps://www.dovepress.com/illustrative-cases-from-the-pathfinder-clinical-trials-of-patients-wit-peer-reviewed-fulltext-article-PPAextended half-lifefactor viiiprophylaxissurgeryjoint health
spellingShingle Klamroth R
Hampton K
Saulyte Trakymienė S
Korsholm L
Carcao M
Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
Patient Preference and Adherence
extended half-life
factor viii
prophylaxis
surgery
joint health
title Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
title_full Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
title_fullStr Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
title_full_unstemmed Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
title_short Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
title_sort illustrative cases from the pathfinder clinical trials of patients with hemophilia a treated with turoctocog alfa pegol n8 gp
topic extended half-life
factor viii
prophylaxis
surgery
joint health
url https://www.dovepress.com/illustrative-cases-from-the-pathfinder-clinical-trials-of-patients-wit-peer-reviewed-fulltext-article-PPA
work_keys_str_mv AT klamrothr illustrativecasesfromthepathfinderclinicaltrialsofpatientswithhemophiliaatreatedwithturoctocogalfapegoln8gp
AT hamptonk illustrativecasesfromthepathfinderclinicaltrialsofpatientswithhemophiliaatreatedwithturoctocogalfapegoln8gp
AT saulytetrakymienes illustrativecasesfromthepathfinderclinicaltrialsofpatientswithhemophiliaatreatedwithturoctocogalfapegoln8gp
AT korsholml illustrativecasesfromthepathfinderclinicaltrialsofpatientswithhemophiliaatreatedwithturoctocogalfapegoln8gp
AT carcaom illustrativecasesfromthepathfinderclinicaltrialsofpatientswithhemophiliaatreatedwithturoctocogalfapegoln8gp